Association of High Expression of Gro<i>β</i> with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">Cytoplasm (%)</td><td align="center">Nucleus (%)</td><td align="center">Cytoplasm + nucleus (%)</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">High GRO<i>β</i> expression</td><td align="center">56 (32.4%)</td><td align="center">64 (37.0%)</td><td align="center">30 (17.3%)</td></tr><tr><td align="left">Low or no GRO<i>β</i> expression</td><td align="center">117 (67.6%)</td><td align="center">109 (63.0%)</td><td align="center">84 (48.6%)</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Expression of GRO<i>β</i> in 173 GISTs with IHC analysis.

Disease Markers

tab1

Table 1

Table 1: Association of High Expression of Gro<i>β</i> with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors 

Table 1 | Association of High Expression of Groβ with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors 